Skip to main content
. 2011 Aug 7;36(12):2363–2372. doi: 10.1007/s11064-011-0562-7

Fig. 4.

Fig. 4

sNgR-Fc increased bromodeoxyuridin incorporation. Merged images of bromodeoxyuridin (BrdU) and 4′,6-diamidino-2-phenylindole (DAPI). The NPCs were treated as described below for 3 days and then pulsed with BrdU (10 μM) for 2 h. a The control group, cultured neural progenitor cells (NPCs) received no further treatment. b–d Cultured NPCs received treatment of different dosage of sNgR-Fc. e Cultured NPCs received treatment with sNgR-Fc (500 ng/ml) plus myelin-associated glycoprotein (MAG). f Cultured NPCs received treatment with sNgR-Fc (500 ng/ml) plus MW167, a Notch1 inhibitor. sNgR-Fc increased the ratio of BrdU-positive neural progenitor cells in dosage-dependent manners, while MAG or MW167 decreased such increased ratio of BrdU incorporation. g A percentage of BrdU-positive cells in total number of cells with different treatments. h The total number of DAPI positive cells five visual fields in different groups. In g, h, *P < 0.05, # P < 0.01 compared with control group. Open triangle P < 0.01 compared to 500 ng/ml group. Six cultures for each group (Mean ± SEM)